Prazer is a Korean biotech company developing orally available, blood-brain barrier (BBB)-penetrating protein degraders through a novel approach to targeted protein degradation (TPD). Since our inception in 2019, Prazer has been committed to redefining the TPD space with our proprietary platform, SPiDEM. Our goal is to overcome the limitations of traditional bivalent and monovalent degraders while synergizing their strengths—such as PROTAC’s versatility and molecular glue’s druglikeness. Prazer focuses on next-generation degraders for a wide range of intractable diseases in neuroscience, oncology, and immunology.